Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

J Moore, Malcolm; Goldstein, David; Hamm, John; Figer, Arie; R Hecht, Joel; Gallinger, Steven; J Au, Heather; Murawa, Pawel; Walde, David; A Wolff, Robert; Campos, Daniel; Lim, Robert; Ding, Keyue; Clark, Gary; Voskoglou-Nomikos, Theodora; Ptasynski, Mieke; Parulekar, Wendy; Cancer Institute of Canada Clinical Trials Group, National

doi:10.1200/jco.2006.07.9525

Public

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Published in Journal of clinical oncology : official journal of the American Society of Clinical Oncology • May 20, 2007

NobleIDark:/48914/w1/20260526/5238173CRecord on NobleID

Authors:

Malcolm J Moore

,

David Goldstein

,

John Hamm

Abstract

PURPOSE: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse pro...

Discussions